Icon of the Instituts for Quality and Efficiency in Health Care

Report

Benefit assessment of bupropion, cytisine, nicotine and varenicline for smoking cessation in severe tobacco dependence

Status
Status: Commission completed
Project no.
A22-34
Last updated

Report documents

  1. Extract of the final report

    Benefit assessment of bupropion, cytisine, nicotine and varenicline for smoking cessation in severe tobacco dependence

    published on
    Document type
    PDF document, 1 MB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A22-34_en
    Download file : Extract of the final report (PDF document, 1 MB, EN, not accessible)

  2. Final report

    Benefit assessment of bupropion, cytisine, nicotine and varenicline for smoking cessation in severe tobacco dependence

    published on
    Document type
    PDF document, 4 MB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A22-34
    Download file : Final report (PDF document, 4 MB, DE, not accessible)

  3. Documentation of comments on the preliminary report

    Benefit assessment of bupropion, cytisine, nicotine and varenicline for smoking cessation in severe tobacco dependence

    published on
    Document type
    PDF document, 1 MB, DE, not accessible
    Download file : Documentation of comments on the preliminary report (PDF document, 1 MB, DE, not accessible)

  4. Preliminary report

    Benefit assessment of bupropion, cytisine, nicotine and varenicline for smoking cessation in severe tobacco dependence

    published on
    Document type
    PDF document, 4 MB, DE, not accessible
    Download file : Preliminary report (PDF document, 4 MB, DE, not accessible)

  5. Documentation of comments on the report plan

    Benefit assessment of bupropion, cytisine, nicotine and varenicline for smoking cessation in severe tobacco dependence

    published on
    Document type
    PDF document, 2 MB, DE, not accessible
    Download file : Documentation of comments on the report plan (PDF document, 2 MB, DE, not accessible)

  6. Report plan

    Benefit assessment of bupropion, cytisine, nicotine and varenicline for smoking cessation in severe tobacco dependence

    published on
    Document type
    PDF document, 416 kB, DE, not accessible
    Download file : Report plan (PDF document, 416 kB, DE, not accessible)

Press releases

Tobacco cessation: IQWiG confirms benefit for nicotine and for varenicline

Tobacco cessation: IQWiG confirms benefit for nicotine and for varenicline
Press release

Smoking cessation in severe tobacco dependence: benefit proven for two of four drugs

Varenicline and nicotine offer clear advantages for smokers who are severely addicted to tobacco. There is a lack of corresponding evidence for bupropion and cytisine and for drug combination therapy. English translation of the final report now available
Press release

Project details

Project no.
A22-34
Commission
Commission awarded on 18.03.2022 by the Federal Joint Committee (GBA).
Report type
Report
Status
Commission completed
Department/Division
Drug Assessment
Topic
Mental and emotional wellbeing
DOI

https://dx.doi.org/10.60584/A22-34

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page